Once again, a big hedge fund is trying to convince the Allergan (AGN) board to split the roles of chairman and chief executive into separate positions and address “chronic underperformance.”

In a brief but pointed letter, Appaloosa Management criticized the board for ignoring the same request last spring and contended its refusal makes the company an “outlier.” In arguing its case, the fund cited ISS Analytics data showing the percentage of S&P 500 companies with dual chairs and chief executives was 45.6 percent in 2018, down from 48.7 percent the year before and the lowest percentage in at least a decade.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy